Developer docs
API playgroundTry for free, no card

Search company profiles

NovaCell Technology

Full company profile

uuid000y3e8

Namestring
NovaCell Technology
Legal namestring
NOVACELL TECHNOLOGY Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

NovaCell Technology Inc. is a South Korean private biotherapeutics company headquartered on the POSTECH campus in Pohang, specializing in peptide-based drug candidates and biomaterials. The company's core technology platform targets FPR2 (Formyl Peptide Receptor 2) with activating peptides designed to promote the body's natural inflammation-resolution process, in contrast to conventional anti-inflammatory approaches that primarily suppress inflammation. Its lead asset, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease that has secured IND approval from South Korea's Ministry of Food and Drug Safety and entered Phase 2 clinical trials under licensee Huons.

NovaCell operates as a technology licensor and pipeline developer rather than a vertically integrated commercial pharmaceutical company. Its primary go-to-market motion is out-licensing proprietary peptide candidates to pharmaceutical partners — most notably the Huons agreement for HUC1-394 — for clinical development and commercialization, generating licensing fees with potential milestone and royalty upside. The company also operates a consumer sub-brand, Novapet, distributed through nationwide pharmacy channels in South Korea. Revenue mechanics are not publicly disclosed, and the company is pursuing a pre-IPO listing with associated capital-raising and reporting milestones active in 2026.

The company's customer base is concentrated in pharmaceutical partners (Huons) and clinical sites (Severance Hospital / Yonsei University College of Medicine for the Phase 2 trial). NovaCell is founder-led under CEO Lee Tae-hoon and has raised approximately $11.16M in disclosed equity funding led by Quantum Ventures Korea with participation from Korea Investment Partners, Huons, Aion Investment Management, and other Korean venture investors. Strategic positioning centers on a differentiated FPR2 mechanism-of-action platform with potential applications across ophthalmology, immunology, and broader inflammatory indications.

Short descriptiontext

NovaCell Technology is a South Korean private biotherapeutics company developing FPR2-targeting peptide drug candidates, with lead asset HUC1-394 in Phase 2 trials for dry eye disease. It operates as a technology licensor to pharmaceutical partners such as Huons and is pursuing a pre-IPO listing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPohang, South Korea
HQ citystring
Pohang
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide biotherapeutics, ophthalmic drug development, dry eye disease treatment, FPR2 targeting peptides, inflammation resolution therapeutics
Industry2 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Peptide-based Biotherapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Licensing
TypeLicensing Royalties
Description

NovaCell generates revenue by licensing its proprietary peptide technology and drug candidates to pharmaceutical companies. The company licensed HUC1-394 (dry eye treatment) to Huons for clinical development and commercialization, receiving licensing fees and potentially milestone payments and royalties.

koreaherald.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NovaCell Technology develops proprietary peptide-based biotherapeutics with a focus on FPR2 (Formyl Peptide Receptor 2) targeting peptides that promote the body's natural inflammation-resolution process. Its lead clinical candidate, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease, currently licensed to Huons for Phase 2 clinical trials in South Korea. The company additionally markets a pet-health product line under the Novapet brand through nationwide pharmacy channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • HUC1-394 peptide-based ophthalmic solution demonstrating novel mechanism in Phase 2 clinical trials for dry eye disease
Product overview1 text field

NovaCell Technology is a global peptide-based biotherapeutics and biomaterial company. The company's core offering is its pipeline of peptide-based drug candidates, with HUC1-394 being the lead candidate — a peptide-based ophthalmic solution for dry eye disease that works through a novel FPR2-mediated inflammation-resolution mechanism. The company operates primarily in the pharmaceutical development space, with ongoing clinical trials and pre-IPO activities.

Product and service2 records
1HUC1-394
CategoryPeptide-based Biotherapeutics / Ophthalmic Drug Candidate
Description

Peptide-based ophthalmic solution for dry eye disease. The novel mechanism works by activating FPR2 (Formyl Peptide Receptor 2) to promote the body's natural inflammation-resolution process, offering a differentiated approach compared to conventional treatments that mainly suppress inflammation. Licensed to Huons for Phase 2 clinical development in South Korea, with trials involving approximately 150 patients at sites including Severance Hospital (Yonsei University College of Medicine).

2Novapet (brand product line)
CategoryPet Health / Consumer Biotherapeutics
Description

Consumer pet-health product line marketed under the Novapet brand, leveraging NovaCell's peptide-based biomaterials and biotherapeutics platform. Distributed nationwide through South Korean pharmacy retail channels.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-12
Description

NovaCell Technology licensed its HUC1-394 peptide-based dry eye treatment candidate to Huons. Huons received Investigational New Drug (IND) approval from South Korea's Ministry of Food and Drug Safety to begin Phase 2 clinical trials for this dry eye treatment. The licensing agreement allows Huons to develop and commercialize the product in South Korea.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global ophthalmic pharmaceutical and device company with established dry eye and ocular surface disease franchises. Broad incumbent operating in the same end market as NovaCell and representing a likely global commercialization partner for differentiated ophthalmic assets.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel ophthalmic therapeutics, including dry eye disease candidates, with a focus on drug delivery innovation. Direct peer to NovaCell given parallel positioning in differentiated dry eye therapeutics development.

TypeRegional player
Description

South Korean biopharmaceutical company with ophthalmology and immunology pipeline assets, including biosimilars and novel therapeutics. Comparable to NovaCell as a Korean regional peer pursuing innovative ophthalmic and inflammatory disease treatments.

TypeRegional player
Description

South Korean pharmaceutical company with established ophthalmic and injectable product lines. Both a strategic partner (licensing HUC1-394) and a regional comparable to NovaCell given parallel presence in Korean ophthalmic specialty pharma.

TypeDirect peer
Description

Specialty ophthalmic pharmaceutical company developing novel water-free drug delivery solutions for dry eye and other ocular surface diseases. Direct peer to NovaCell in the differentiated dry eye therapeutics space with similar licensing-driven commercialization approach.

6Yuyu Pharma
TypeRegional player
Description

South Korean pharmaceutical company with ophthalmology and consumer health product lines. Regional peer comparable to NovaCell given overlapping Korean ophthalmic market presence and similar pre-IPO/late-stage clinical development profile.

TypeDirect peer
Description

Clinical-stage ophthalmic specialty company developing novel therapies for rare and serious eye diseases. Comparable to NovaCell as a small-cap clinical-stage ophthalmology company pursuing differentiated mechanisms with licensing partnerships.

TypeDirect peer
Description

Clinical-stage biotech developing novel mechanisms for inflammatory eye diseases, including dry eye disease (reproxalap). Direct peer to NovaCell given the shared focus on differentiated inflammation-targeting ophthalmology therapeutics and Phase-stage development model.

9RegeneRx Biopharmaceuticals
TypeEmerging player
Description

Clinical-stage peptide therapeutics company developing TB4-based treatments for ophthalmic and tissue repair indications. Emerging peer to NovaCell in the peptide-based ophthalmic biotherapeutics space with similar licensing-driven strategy.

TypeBroad incumbent
Description

Ophthalmic specialty pharmaceutical company focused on novel therapies for glaucoma and other eye diseases (now part of Alcon). Broad incumbent comparable to NovaCell given similar specialty ophthalmology positioning and partner-driven commercial model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovaCell Technology

Peptide-based Biotherapeuticsnovacelltech.com

NovaCell Technology is a South Korean private biotherapeutics company developing FPR2-targeting peptide drug candidates, with lead asset HUC1-394 in Phase 2 trials for dry eye disease. It operates as a technology licensor to pharmaceutical partners such as Huons and is pursuing a pre-IPO listing.

What NovaCell Technology does

NovaCell Technology Inc. is a South Korean private biotherapeutics company headquartered on the POSTECH campus in Pohang, specializing in peptide-based drug candidates and biomaterials. The company's core technology platform targets FPR2 (Formyl Peptide Receptor 2) with activating peptides designed to promote the body's natural inflammation-resolution process, in contrast to conventional anti-inflammatory approaches that primarily suppress inflammation. Its lead asset, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease that has secured IND approval from South Korea's Ministry of Food and Drug Safety and entered Phase 2 clinical trials under licensee Huons.

NovaCell operates as a technology licensor and pipeline developer rather than a vertically integrated commercial pharmaceutical company. Its primary go-to-market motion is out-licensing proprietary peptide candidates to pharmaceutical partners — most notably the Huons agreement for HUC1-394 — for clinical development and commercialization, generating licensing fees with potential milestone and royalty upside. The company also operates a consumer sub-brand, Novapet, distributed through nationwide pharmacy channels in South Korea. Revenue mechanics are not publicly disclosed, and the company is pursuing a pre-IPO listing with associated capital-raising and reporting milestones active in 2026.

The company's customer base is concentrated in pharmaceutical partners (Huons) and clinical sites (Severance Hospital / Yonsei University College of Medicine for the Phase 2 trial). NovaCell is founder-led under CEO Lee Tae-hoon and has raised approximately $11.16M in disclosed equity funding led by Quantum Ventures Korea with participation from Korea Investment Partners, Huons, Aion Investment Management, and other Korean venture investors. Strategic positioning centers on a differentiated FPR2 mechanism-of-action platform with potential applications across ophthalmology, immunology, and broader inflammatory indications.

NovaCell Technology firmographics

Firmographics
Name
NovaCell Technology
Legal name
NOVACELL TECHNOLOGY Inc.
Website
https://novacelltech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
NovaCell Technology is a South Korean private biotherapeutics company developing FPR2-targeting peptide drug candidates, with lead asset HUC1-394 in Phase 2 trials for dry eye disease. It operates as a technology licensor to pharmaceutical partners such as Huons and is pursuing a pre-IPO listing.
Ownership category
akta.pro rank

NovaCell Technology industry classification

Industry
Product category
Peptide-based Biotherapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Peptide biotherapeutics
  • Ophthalmic drug development
  • Dry eye disease treatment
  • FPR2 targeting peptides
  • Inflammation resolution therapeutics

Where NovaCell Technology is headquartered

Location

Headquarters

HQ city
Pohang
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

NovaCell Technology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: NovaCell generates revenue by licensing its proprietary peptide technology and drug candidates to pharmaceutical companies. The company licensed HUC1-394 (dry eye treatment) to Huons for clinical development and commercialization, receiving licensing fees and potentially milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

NovaCell Technology product offering

Product offering

Core offering

NovaCell Technology develops proprietary peptide-based biotherapeutics with a focus on FPR2 (Formyl Peptide Receptor 2) targeting peptides that promote the body's natural inflammation-resolution process. Its lead clinical candidate, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease, currently licensed to Huons for Phase 2 clinical trials in South Korea. The company additionally markets a pet-health product line under the Novapet brand through nationwide pharmacy channels.

Product overview

NovaCell Technology is a global peptide-based biotherapeutics and biomaterial company. The company's core offering is its pipeline of peptide-based drug candidates, with HUC1-394 being the lead candidate — a peptide-based ophthalmic solution for dry eye disease that works through a novel FPR2-mediated inflammation-resolution mechanism. The company operates primarily in the pharmaceutical development space, with ongoing clinical trials and pre-IPO activities.

Differentiator

Problem solved

Functional benefit

Products and services

  • HUC1-394 Peptide-based ophthalmic solution for dry eye disease. The novel mechanism works by activating FPR2 (Formyl Peptide Receptor 2) to promote the body's natural inflammation-resolution process, offering a differentiated approach compared to conventional treatments that mainly suppress inflammation. Licensed to Huons for Phase 2 clinical development in South Korea, with trials involving approximately 150 patients at sites including Severance Hospital (Yonsei University College of Medicine).
  • Novapet (brand product line) Consumer pet-health product line marketed under the Novapet brand, leveraging NovaCell's peptide-based biomaterials and biotherapeutics platform. Distributed nationwide through South Korean pharmacy retail channels.

Quantifiable outcome

  • HUC1-394 peptide-based ophthalmic solution demonstrating novel mechanism in Phase 2 clinical trials for dry eye disease

Companies that use NovaCell Technology

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

NovaCell Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

NovaCell Technology partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HuonscoreTechnology or Integration · 12 March 2026NovaCell Technology licensed its HUC1-394 peptide-based dry eye treatment candidate to Huons. Huons received Investigational New Drug (IND) approval from South Korea's Ministry of Food and Drug Safety to begin Phase 2 clinical trials for this dry eye treatment. The licensing agreement allows Huons to develop and commercialize the product in South Korea.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

NovaCell Technology competitors and assessment

Company assessment

Broad incumbents

  • Bausch + Lomb: Global ophthalmic pharmaceutical and device company with established dry eye and ocular surface disease franchises. Broad incumbent operating in the same end market as NovaCell and representing a likely global commercialization partner for differentiated ophthalmic assets.
  • Aerie Pharmaceuticals: Ophthalmic specialty pharmaceutical company focused on novel therapies for glaucoma and other eye diseases (now part of Alcon). Broad incumbent comparable to NovaCell given similar specialty ophthalmology positioning and partner-driven commercial model.

Direct peers

  • Ocular Therapeutix: Clinical-stage biopharmaceutical company developing novel ophthalmic therapeutics, including dry eye disease candidates, with a focus on drug delivery innovation. Direct peer to NovaCell given parallel positioning in differentiated dry eye therapeutics development.
  • Novaliq: Specialty ophthalmic pharmaceutical company developing novel water-free drug delivery solutions for dry eye and other ocular surface diseases. Direct peer to NovaCell in the differentiated dry eye therapeutics space with similar licensing-driven commercialization approach.
  • Kala Bio: Clinical-stage ophthalmic specialty company developing novel therapies for rare and serious eye diseases. Comparable to NovaCell as a small-cap clinical-stage ophthalmology company pursuing differentiated mechanisms with licensing partnerships.
  • Aldeyra Therapeutics: Clinical-stage biotech developing novel mechanisms for inflammatory eye diseases, including dry eye disease (reproxalap). Direct peer to NovaCell given the shared focus on differentiated inflammation-targeting ophthalmology therapeutics and Phase-stage development model.

Regional players

  • HanAll Biopharma: South Korean biopharmaceutical company with ophthalmology and immunology pipeline assets, including biosimilars and novel therapeutics. Comparable to NovaCell as a Korean regional peer pursuing innovative ophthalmic and inflammatory disease treatments.
  • Huons Global: South Korean pharmaceutical company with established ophthalmic and injectable product lines. Both a strategic partner (licensing HUC1-394) and a regional comparable to NovaCell given parallel presence in Korean ophthalmic specialty pharma.
  • Yuyu Pharma: South Korean pharmaceutical company with ophthalmology and consumer health product lines. Regional peer comparable to NovaCell given overlapping Korean ophthalmic market presence and similar pre-IPO/late-stage clinical development profile.

Emerging players

  • RegeneRx Biopharmaceuticals: Clinical-stage peptide therapeutics company developing TB4-based treatments for ophthalmic and tissue repair indications. Emerging peer to NovaCell in the peptide-based ophthalmic biotherapeutics space with similar licensing-driven strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NovaCell Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovaCell Technology leadership team

Management profile

Number of profiles

Profiles1 record

NovaCell Technology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovaCell Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaCell Technology

What does NovaCell Technology do?

NovaCell Technology develops proprietary peptide-based biotherapeutics with a focus on FPR2 (Formyl Peptide Receptor 2) targeting peptides that promote the body's natural inflammation-resolution process. Its lead clinical candidate, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease, currently licensed to Huons for Phase 2 clinical trials in South Korea. The company additionally markets a pet-health product line under the Novapet brand through nationwide pharmacy channels.

Is NovaCell Technology a public or private company?

NovaCell Technology is a private company. It is classified as venture growth investor backed and is currently operating.

When was NovaCell Technology founded?

NovaCell Technology was founded in 2018. It employs 51 to 100 people.

Where is NovaCell Technology based?

NovaCell Technology is headquartered in Pohang, South Korea, in the Asia region.

How does NovaCell Technology make money?

One revenue line is on record: technology Licensing.

Who are NovaCell Technology's main competitors?

Broad incumbents on record are Bausch + Lomb and Aerie Pharmaceuticals. Direct peers are Ocular Therapeutix, Novaliq, Kala Bio and Aldeyra Therapeutics. Regional players are HanAll Biopharma, Huons Global and Yuyu Pharma. RegeneRx Biopharmaceuticals is listed as an emerging player.

Does NovaCell Technology have an API?

No public API is recorded for NovaCell Technology.

What industry is NovaCell Technology in?

NovaCell Technology's product category is Peptide-based Biotherapeutics. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales